pharmastocks

#EarningsSeason
🚀 $LLY Earnings Preview: Can Weight-Loss Drug Demand Drive a Bullish Breakout?

💊 $LLY reports Q3 2026 earnings on October 29. Analysts expect strong revenue growth, driven by rising demand for Mounjaro and Zepbound, its diabetes and weight-loss treatments. However, earnings expectations and drug pricing pressures could influence the market reaction.

📊 My Prediction is Bullish on LLY.

Why? Strong demand for obesity and diabetes drugs could support revenue growth, while future pipeline developments offer additional growth potential. The key catalysts are earnings results, forward guidance, and sales momentum.

🎯 Question: How do you expect $LLY stock to move after earnings—BULLISH 📈 or BEARISH 📉?

#LLY #EarningsSeason #StockMarket #PharmaStocks #Investing